Adia Labs Secures FDA Registration for Adia Vita, Expands Regenerative Medicine Nationwide
ADIA Nutrition (OTC Pink: ADIA) announces FDA registration acceptance for Adia Vita, its subsidiary Adia Labs' premier stem cell product. The product contains a minimum of 100 million viable cells and 3 trillion exosomes per unit.
The registration enables nationwide distribution to doctors and clinics, making advanced regenerative medicine more accessible. While typical stem cell therapies cost between $15,000-$35,000 per treatment, Adia Med aims to offer their superior product at a reduced price point.
The company is now actively expanding its reach across the United States, targeting healthcare providers and medical professionals to enhance patient care and support clinical research in various health conditions.
ADIA Nutrition (OTC Pink: ADIA) annuncia l'accettazione della registrazione da parte della FDA per Adia Vita, il prodotto di punta della sua sussidiaria Adia Labs nel campo delle cellule staminali. Il prodotto contiene un minimo di 100 milioni di cellule vitali e 3 trilioni di esosomi per unità.
La registrazione consente la distribuzione a livello nazionale a medici e cliniche, rendendo la medicina rigenerativa avanzata più accessibile. Mentre le terapie tradizionali con cellule staminali costano tra i 15.000 e i 35.000 dollari per trattamento, Adia Med punta a offrire il proprio prodotto superiore a un prezzo ridotto.
L'azienda sta ora attivamente espandendo la propria portata negli Stati Uniti, mirando a fornitori di assistenza sanitaria e professionisti medici per migliorare la cura dei pazienti e supportare la ricerca clinica in diverse condizioni di salute.
ADIA Nutrition (OTC Pink: ADIA) anuncia la aceptación de la registración por parte de la FDA para Adia Vita, el producto principal de su subsidiaria Adia Labs en el ámbito de las células madre. El producto contiene un mínimo de 100 millones de células viables y 3 billones de exosomas por unidad.
La registración permite la distribución a nivel nacional a médicos y clínicas, haciendo que la medicina regenerativa avanzada sea más accesible. Mientras que las terapias típicas con células madre cuestan entre $15,000 y $35,000 por tratamiento, Adia Med busca ofrecer su producto superior a un precio reducido.
La compañía está ahora expandiendo activamente su alcance en los Estados Unidos, enfocándose en proveedores de atención médica y profesionales médicos para mejorar la atención al paciente y apoyar la investigación clínica en diversas condiciones de salud.
ADIA Nutrition (OTC Pink: ADIA)는 Adia Vita의 FDA 등록 수락을 발표했습니다. 이는 자회사 Adia Labs의 주요 줄기세포 제품입니다. 이 제품은 단위당 최소 1억 개의 생존 세포와 3조 개의 외소포를 포함하고 있습니다.
이 등록은 의사와 클리닉에 대한 전국적인 유통을 가능하게 하여 고급 재생 의학을 보다 접근 가능하게 만듭니다. 일반적인 줄기세포 치료는 치료당 15,000달러에서 35,000달러 사이의 비용이 드는 반면, Adia Med는 자사의 우수한 제품을 낮은 가격에 제공할 계획입니다.
회사는 현재 미국 전역으로의 확장을 적극적으로 진행하고 있으며, 의료 제공자와 의료 전문가를 대상으로 환자 치료를 개선하고 다양한 건강 상태에 대한 임상 연구를 지원하고 있습니다.
ADIA Nutrition (OTC Pink: ADIA) annonce l'acceptation de l'enregistrement par la FDA pour Adia Vita, le produit phare de sa filiale Adia Labs dans le domaine des cellules souches. Le produit contient un minimum de 100 millions de cellules viables et 3 trillions d'exosomes par unité.
L'enregistrement permet une distribution à l'échelle nationale aux médecins et aux cliniques, rendant la médecine régénérative avancée plus accessible. Alors que les thérapies typiques par cellules souches coûtent entre 15 000 et 35 000 dollars par traitement, Adia Med vise à offrir son produit supérieur à un prix réduit.
La société est désormais en train d'élargir activement sa portée à travers les États-Unis, ciblant les prestataires de soins de santé et les professionnels médicaux pour améliorer les soins aux patients et soutenir la recherche clinique sur diverses conditions de santé.
ADIA Nutrition (OTC Pink: ADIA) gibt die Annahme der FDA-Registrierung für Adia Vita, das Hauptprodukt der Tochtergesellschaft Adia Labs im Bereich der Stammzellen, bekannt. Das Produkt enthält mindestens 100 Millionen lebensfähige Zellen und 3 Billionen Exosomen pro Einheit.
Die Registrierung ermöglicht die landesweite Verteilung an Ärzte und Kliniken und macht fortschrittliche regenerative Medizin zugänglicher. Während typische Stammzelltherapien zwischen 15.000 und 35.000 Dollar pro Behandlung kosten, zielt Adia Med darauf ab, sein überlegendes Produkt zu einem reduzierten Preis anzubieten.
Das Unternehmen erweitert nun aktiv seine Reichweite in den Vereinigten Staaten und richtet sich an Gesundheitsdienstleister und medizinisches Fachpersonal, um die Patientenversorgung zu verbessern und klinische Forschung zu verschiedenen Gesundheitszuständen zu unterstützen.
- FDA registration secured for Adia Vita stem cell product
- Nationwide distribution authorization achieved
- Product offers premium quality (100M viable cells, 3T exosomes)
- Competitive pricing strategy below market range ($15K-35K)
- Immediate revenue generation potential through nationwide sales
- Operating in highly competitive regenerative medicine market
- Lower pricing strategy may impact profit margins
Winter Park, Florida--(Newsfile Corp. - March 3, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a trailblazer in healthcare innovation, proudly announces a major milestone for its new subsidiary, Adia Labs LLC: the FDA has accepted the registration of Adia Vita. This acceptance reflects Adia Labs' notification to the FDA that it will be storing and distributing its premier stem cell product, Adia Vita, to doctors and clinics nationwide, broadening access to cutting-edge regenerative medicine and significantly increasing revenue potential.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/242494_adia1.jpg
Adia Labs is thrilled to introduce Adia Vita, a top-tier product featuring umbilical cord stem cells with a minimum of 100 million viable cells and 3 trillion exosomes per unit. For people unfamiliar with regenerative medicine, stem cell therapies-such as those provided by Adia Med-usually cost between
"Registering Adia Vita with the FDA marks a game-changing moment for us," said Larry Powalisz, CEO of ADIA Nutrition. "We're deeply grateful to the FDA for their timely and cooperative efforts in making this registration possible so quickly. This milestone allows us to reach a vast network of doctors and clinics across the country, offering a high-quality, cost-effective solution that accelerates client growth. We're excited to lead the charge in making advanced patient care more affordable and widespread." Powalisz added, "As of this moment, we are open for business on this front, and we invite any and all medical professionals across the U.S. to give us a call at 321-788-0850 to explore how Adia Vita can enhance their practice."
This FDA registration empowers Adia Labs to expand its reach, connecting healthcare providers nationwide with Adia Vita. By offering a premium product at a lower cost than the typical
Adia Labs looks forward to rolling out Adia Vita, bringing hope and affordable, high-quality treatment options to patients battling a wide range of health challenges.
For any questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242494
FAQ
What is the cell count in ADIA's newly FDA-registered Adia Vita product?
How much do typical stem cell treatments cost compared to ADIA's offering?
What does the FDA registration mean for ADIA's market reach?
When did ADIA receive FDA registration for Adia Vita?
What is the potential market impact of ADIA's nationwide distribution approval?
